share_log

HC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Target

HC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price Target

HC Wainwright & Co.重申買入Medicenna Therapeutics,維持2.5美元的目標股價
Benzinga ·  2023/07/31 05:16

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and maintains $2.5 price target.

HC Wainwright&Co.分析師Swayampakula Ramakanth重申美第奇拿治療公司(納斯達克:mDNA)的買入,並維持2.5美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論